氟喹诺酮暴露对免疫抑制结核患者诊断与预后的影响
结果显示,氟喹诺酮暴露未显著延迟微生物学诊断或抗结核治疗启动,也与90天全因死亡及结核相关死亡无显著关联。
要点
- 在373例漏诊的免疫抑制结核患者中,97例(26%)在抗结核治疗前接受过经验性氟喹诺酮治疗。
- 倾向评分匹配后,氟喹诺酮暴露组与未暴露组的微生物学诊断中位时间分别为21天(IQR 17-29)和21天(IQR 17.5-27),P=0.75。
- 氟喹诺酮暴露与90天全因死亡无显著关联(P=0.44),与结核相关死亡的亚分布风险比为1.53(95%CI 0.26-9.03,P=0.64)。
核心结论
- 在免疫抑制结核患者中,氟喹诺酮暴露未对诊断时间或死亡结局产生不良影响。
研究设计与样本
- 根据氟喹诺酮暴露分组,进行倾向评分匹配、生存分析和竞争风险分析,评估氟喹诺酮暴露与诊断时间线及患者死亡率的关联。
主要发现
- 在373例漏诊的免疫抑制患者中,97例(26%)在抗结核治疗前接受过经验性氟喹诺酮治疗,并按1:1倾向评分匹配至97例未接受氟喹诺酮治疗的患者。
- 采样前氟喹诺酮暴露未显著延迟微生物学诊断时间(中位21天,IQR 17-29 vs 21天,IQR 17.5-27,P=0.75)或抗结核治疗启动时间(中位27天,IQR 21-34.75 vs 28天,IQR 22-38,P=0.76)。
- 生存分析显示氟喹诺酮暴露与90天全因死亡率无显著关联(P=0.44),竞争风险分析显示氟喹诺酮暴露与结核相关死亡无显著关联(亚分布风险比1.53,95%CI 0.26-9.03,P=0.64)。
临床怎么用
- 对于免疫抑制患者,在明确结核诊断前经验性使用氟喹诺酮可能不会对后续诊断时间或死亡结局产生显著不良影响。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Tuberculosis (TB) in immunocompromised patients presents a significant diagnostic challenge. These patients are sometimes empirically treated with quinolones before a definitive diagnosis is established. However, there are limited data on the impact of fluoroquinolone exposure on TB diagnosis and outcomes in these patients. METHODS: We retrospectively analysed immunocompromised adults with missed TB diagnoses who did not receive anti-TB therapy before obtaining positive mycobacterial culture results, from January 2011 to December 2023. Patients were categorized according to their fluoroquinolone exposure. Propensity score matching, survival analysis, and competing risk analysis were performed to evaluate the association between fluoroquinolone exposure and its impact on diagnostic timelines and patient mortality. RESULTS: Among 373 immunocompromised patients with missed diagnosis, 97 (26%) received empirical fluoroquinolone therapy before anti-TB therapy. These patients were propensity-score-matched 1:1 to 97 patients who did not receive fluoroquinolone therapy. Fluoroquinolone exposure before sampling did not significantly delay the time to microbiological diagnosis (median 21 days, IQR 17-29 versus 21 days, IQR 17.5-27, P = 0.75) or initiation of anti-TB therapy (median 27 days, IQR 21-34.75 versus 28 days, IQR 22-38, P = 0.76). Survival analysis showed that fluoroquinolone exposure was not significantly associated with 90-day all-cause mortality (P = 0.44), and competing risk analysis showed that fluoroquinolone exposure was not significantly associated with TB-related death (sub-distribution hazard ratio 1.53, 95% CI 0.26-9.03, P = 0.64). CONCLUSION: Fluoroquinolone exposure in immunocompromised patients with TB did not adversely affect diagnostic timelines or mortality outcomes.
引用
- Kang SW, Jang HM, Chang E, et al. Impact of fluoroquinolone exposure on the diagnosis and prognosis of tuberculosis in immunocompromised patients: a propensity-score-matched, competing risk analysis. J Antimicrob Chemother. 2025. PMID: 40192420. doi:10.1093/jac/dkaf111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。